Skip Navigation

Cardiovascular Research 2003 57(1):277-283; doi:10.1016/S0008-6363(02)00658-2
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rossi, G. P.
Right arrow Articles by Pessina, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossi, G. P.
Right arrow Articles by Pessina, A. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension

Gian Paolo Rossia,*, Chiara Ganzarolia, Maurizio Cesaria, Andrea Marescaa, Mario Plebanib, Gastone G. Nussdorferc and Achille C. Pessinaa

aDepartment of Clinical and Experimental Medicine, Clinica Medica 4, University Hospital, via Giustiniani 2, 35126 Padova, Italy
bDepartment of Laboratory Medicine, University of Padova, Padova, Italy
cAnatomy Section, Department of Human Anatomy and Physiology, University of Padova, Padova, Italy

* Corresponding author. Tel.: +39-049-821-3304/2301; fax: +39-049-880-2252. gianpaolo.rossi{at}unipd.it

Background: Endothelin (ET)-1 contributes to raising blood pressure (BP) and inducing cardiovascular disease by vasoconstriction and potent stimulation of aldosterone secretion. In the rat this latter effect occurs via ETB receptors; in humans in vitro studies implicated both ETA and ETB receptors, but there is no conclusive evidence in vivo. Methods: We recruited 13 consenting hypertensive patients: six with primary aldosteronism (PA) and seven with high-to-normal renin hypertension (HNRH). They were infused with a low dose (200 nmol/min for 5 min followed by 100 nmol/min for 10 min) of the ETA-selective antagonist BQ-123 either alone or, on a different day, together with an identical dose of the ETB-selective antagonist BQ-788. Plasma aldosterone, cortisol and ACTH concentration and plasma renin activity (PRA) were measured with radioimmunoassay at –15, 0, 30, 60, 120, 240, 360 min, while BP was recorded non-invasively. Results: BQ-123 alone and combined with BQ-788 significantly lowered mean BP in both PA and HNRH patients (by 6–10 mmHg at nadir; P<0.01). In PA patients, a short-lived decrease of aldosterone was elicited by combined BQ-123 and BQ-788 (–14%; P<0.05), but not by BQ-123 alone; cortisol, ACTH, and PRA were unaffected by either treatment. In HNRH patients, BQ-123 both alone and combined with BQ-788 lowered aldosterone (–39 and –28%, respectively) and PRA (–43 and –16%, respectively), while cortisol and ACTH were unaffected. Conclusions: Endogenous ET-1 contributes to maintaining the high BP values and the aldosterone secretion in both PA and HNRH patients. In the former patients, the aldosterone secretagogue effect of ET-1 is mediated via ETB receptors, while in the latter it occurs mainly via ETA-mediated stimulation of renin production.

KEYWORDS Blood pressure; Endothelins; Hypertension; Receptors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.